Psychedelics Companies Could Look Different by End of Biotech Rout
A lab worker processes psilocybin mushrooms.
Photographer: James MacDonald/BloombergWelcome to my weekly newsletter on the cannabis and psychedelics industries. I’m trying something different this week and publishing a story with a related piece in the newsletter. Let me know what you think.
Investors in the psychedelics industry have long said its companies are like biotech stocks, but with an edge.